logo
Pennsylvania cop died by suicide after suffering nightmare complications from Lasik eye surgery

Pennsylvania cop died by suicide after suffering nightmare complications from Lasik eye surgery

New York Post21-05-2025
A young Pennsylvania police officer took his own life after he suffered from side effects caused by elective eye surgery, according to his family.
Ryan Kingerski, 26, took time off from his job at the Penn Hills Police Department in August to undergo the popular eye surgery, LASIK, in hopes it would improve his vision, his grieving parents, Tim and Stefanie Kingerski, told CBS News Tuesday.
However, he began suffering from painful side effects, including headaches, double vision, seeing dark spots and floaters — tiny spots that appear as streaks or cobweb-like shapes across a person's field of vision, they said.
Advertisement
6 Police officer Ryan Kingerski took his life after suffering from complications following LASIK eye surgery.
Family Handout
His parents said their son was 'full of regret,' and they tried finding specialists in hopes of locating some remedy to help with his pain, but nothing was helping.
The young police officer then killed himself in January — five months after the surgery.
Advertisement
'He left us a note that said, 'I can't take this anymore. LASIK took everything from me.' That's the note that we got left,' his dad told CBS News.
'That's what we were left with,' his heartbroken mother added.
The cop was 'witty, charming, smart' and had a passion for police work from a young age, his parents said. He followed in his father's footsteps, and along with his twin brother Jacob, they both became cops.
6 His grieving parents, Stefanie and Tim Kingerski, said they never imagined what harm the side effects could cause.
WTAE
Advertisement
When Kingerski eventually told his parents that he wanted to undergo the surgery, they said they were more worried about the dangers he faced on the street as a police officer.
'We had no thought of that,' his mother said, with Tim adding they believed LASIK was a 'simple and effective, routine surgery' that would have him 'back to work in a couple of days.'
However, their son never returned to duty.
'It just … it ruined his life. Ruined it. Completely ruined his life in 12 seconds,' Tim told WTAE News.
Advertisement
6 His parents said that they were more worried about the dangers their son faced on the street as a police officer than about him undergoing the surgery.
CBS Pittsburgh
Kingerski's parents said the pain of losing their son is unimaginable — and decided to share his story with others before they consider undergoing LASIK just as he would have if he were still alive.
'He didn't want anyone else to ever feel the same way, and he wanted people to know the facts,' Stefanie said.
LASIK, which stands for 'Laser-Assisted In Situ Keratomileusis,' was approved by the FDA for correction of refractive errors, such as nearsightedness (myopia), farsightedness (hyperopia), and astigmatism, in 1999.
6 The young police officer committed suicide in January — five months after the surgery.
Family Handout
The former head of the FDA branch responsible for reviewing data and approving LASIK decades ago, Morris Waxler, told WTAE News that the surgery was originally approved for 100 clinical trials, but he left the organization soon after.
He has since petitioned the FDA to withdraw its approval of LASIK over the years, but was denied.
Waxler also reiterated that Kingerski's story should not be ignored.
Advertisement
'They cut nerves, then, in addition, they take out a divot, which removes all the support structure or muscle out of the support section and all of it,' Waxler said.
6 LASIK, which stands for 'Laser-Assisted In Situ Keratomileusis,' was approved by the FDA for correction of refractive errors, such as nearsightedness (myopia), farsightedness (hyperopia), and astigmatism, in 1999.
michaelvaulin – stock.adobe.com
'Sometimes it grows back, sometimes it doesn't grow back, sometimes it grows back poorly. For some people, it's a bigger problem than others.'
It's estimated that 700,000 to 800,000 people undergo LASIK surgeries every year in the US, according to the National Institutes of Health.
Advertisement
The rate of serious, sight-threatening LASIK complications is less than 1%, according to the American Refractive Surgery Council.
6 His parents — who described their son as 'witty, charming, smart,' who had a passion for police work from a young age — followed in his father's footsteps, and along with his twin brother Jacob, they both became cops.
Family Handout
Kingerski's parents still encourage anyone thinking about getting the surgery to do extensive research beforehand, and stressed anyone suffering with complications from LASIK to join support groups and reach out for crisis and suicide prevention services if they feel as their son did.
If you are struggling with suicidal thoughts or are experiencing a mental health crisis and live in New York City, you can call 1-888-NYC-WELL for free and confidential crisis counseling. If you live outside the five boroughs, you can dial the 24/7 National Suicide Prevention hotline at 988 or go to SuicidePreventionLifeline.org.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Listeria causes a recall of freeze dried fruit from Sam's Clubs across 42 states
Listeria causes a recall of freeze dried fruit from Sam's Clubs across 42 states

Miami Herald

time5 hours ago

  • Miami Herald

Listeria causes a recall of freeze dried fruit from Sam's Clubs across 42 states

Freeze dried fruit got pulled from Sam's Club locations in 42 states and Puerto Rico because they might be contaminated with listeria. Doehler Dry Ingredient Solutions, which makes Member's Mark Freeze Dried Fruit Variety Packs for Walmart's warehouse club, on Wednesday announced a recall of 22 lots of 15-count boxes. Listeria hits only about 1,600 people in the United States each year, according to the CDC, but about 260 of them die. The most vulnerable people to the worst from listeria are infants and senior citizens. Pregnant women can suffer miscarriages and stillbirths. Usually, people suffer flu-like symptoms, fever, headaches, muscle stiffness, sometimes confusion and/or seizures. The company-written, FDA-posted recall notice said Doehler 'discovered the problem via internal testing of its products. The products were distributed between July 1, 2025 and July 25 and sold in Sam's Club retail stores.' This covers lot Nos. 25175-25177; 25181-25184; 25186; 25188-25192; 25196-25199; and 25202-25206. These lots went to Sam's Club locations in: Florida; California; North Carolina; South Carolina; Missouri; Texas; Georgia; Illinois; Pennsylvania; Mississippi; Alabama; Arizona; Colorado; Connecticut; Delaware; Hawaii; Iowa; Idaho; Indiana; Kansas; Louisiana; Maryland; Maine; Michigan; Minnesota; Montana; North Dakota; South Dakota; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York; Ohio; Oklahoma; Tennessee; Utah; Virginia; Wisconsin; West Virginia; Wyoming; and Puerto Rico. If you have any of the recalled packs, either throw them away or return to to Sam's Club for a refund. Direct any questions about the recall to Doehler at 770-387-0451, Monday through Friday, 8 a.m. to 5 p.m., Eastern time.

‘Combat Cocktail': How America Overmedicates Veterans
‘Combat Cocktail': How America Overmedicates Veterans

Wall Street Journal

time5 hours ago

  • Wall Street Journal

‘Combat Cocktail': How America Overmedicates Veterans

Hundreds of thousands of veterans with PTSD have been prescribed simultaneous doses of powerful psychiatric drugs. The practice, known as 'polypharmacy,' can tranquilize patients to the point of numbness, cause weight gain and increase suicidal thoughts when it involves pharmaceuticals that target the central nervous system, according to scientific studies and veterans' accounts. The VA's own guidelines say no data support drug combinations to treat PTSD. The Food and Drug Administration warns that combining certain medications such as opioids and benzodiazepines can cause serious side effects, including death.

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

Yahoo

time5 hours ago

  • Yahoo

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic cardiovascular disease (ASCVD) patients do not reach guideline-recommended LDL-C target, reinforcing urgent need for more aggressive LDL-C lowering2-5 Twice-yearly Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment EAST HANOVER, N.J., July 31, 2025 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia1. The FDA proactively requested the label update based on the robust LDL-C lowering data for PCSK9-targeting therapies. "This first-line label update reinforces Leqvio's proven ability to effectively lower LDL-C, a critical risk factor for heart disease," said Victor Bultó, President, US, Novartis. "With this new indication enabling Leqvio's use as monotherapy along with diet and exercise, we now have the potential to help even more patients achieve their LDL-C lowering goals earlier in their treatment journey." With its twice-yearly, health care provider-administered dosing, Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment. This is a critical unmet need, as up to 80% of ASCVD patients in the US struggle to reach the LDL-C guideline-recommended target of <70 mg/dL2-5. This need is heightened by the latest 2025 ACC/AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes, which recommends more aggressive treatment to achieve LDL-C targets6. The updated label removes the requirement for Leqvio to be used on top of or in combination with statin therapy1. Other updates include revising "primary hyperlipidemia" to the more specific term of "hypercholesterolemia" throughout the label, to more accurately focus on LDL-C reduction1. *After an initial dose and another at three months. About LeqvioLeqvio is an injectable prescription medicine indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics. Important Safety InformationDo not use if you have had an allergic reaction to Leqvio or any of its ingredients. The most common side effects of Leqvio were injection site reaction (including pain, redness, and rash), arthralgia (joint pain), bronchitis (chest cold). These are not all the possible side effects of Leqvio. Ask your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please click here for Leqvio full Prescribing Information. About Atherosclerotic Cardiovascular Disease (ASCVD)Cardiovascular disease (CVD) affects hundreds of millions of people and claims more lives globally than cancer, chronic lung disease and diabetes combined7. Around 80% of premature cardiovascular deaths can be prevented by addressing factors that cause or worsen accounts for 85% of all CV deaths5,9-11. Its burden in the US is greater than that of any other chronic diseases5,9-11. ASCVD is caused by the development and growth of plaques in the inner lining of the arteries12. The atherosclerotic plaque is mainly composed of low-density lipoprotein cholesterol (LDL-C) that accumulates over time13. Cumulative exposure to LDL-C can increase one's risk of cardiovascular events such as a heart attack or stroke12,13. About Novartis in Cardiovascular DiseaseAt Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We're proud of the positive impact we've made over the past 40 years and remain dedicated to tackling the most challenging problems in CVD. Through cutting-edge science and technology, we are focusing on areas of high unmet need, including scaling our xRNA platform across multiple risk factors and pioneering breakthroughs for genetically driven CVD risk factors and common heart conditions, including atrial fibrillation. We also work with patients, healthcare professionals, and organizations around the world to improve CV care beyond medicine alone. Together, we can help people with CVD enjoy longer, healthier lives and more time with their loved ones. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About NovartisNovartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn US, X/Twitter US and Instagram. References Leqvio. Prescribing information. Novartis Pharmaceuticals Corp Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/ Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1016/ Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-2237. doi:10.1016/ American Heart Association. More than half of U.S. adults don't know heart disease is leading cause of death, despite 100-year reign. Published January 24, 2024. Accessed July 25, 2025. World Heart Federation. World Heart Report 2023: confronting the world's number one killer. Published May 20, 2023. Accessed July 25, 2025. World Health Organization. Cardiovascular diseases (CVDs). Published June 11, 2021. Accessed July 25, 2025. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220. doi:10.1161/CIR.0b013e31823ac046 Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019;19(1):1112. doi:10.1186/s12889-019-7439-0 Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161-172. doi:10.1016/ Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(10):1141-1156. doi:10.1016/ ### Novartis Media Relations E-mail: Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: original content: SOURCE Novartis Pharmaceuticals Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store